Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
García, R
Pérez, P
Alfonso, R
Pérez-Manga, G
Díaz-Rubio, E
机构：
[1] Hosp Gen Gregorio Maranon, Madrid, Spain
[2] H Clin San Carlos, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
528P
引用
收藏
页码：116 / 116
页数：1
相关论文
共 50 条
  • [41] Histologic review of second-line permetrexed treatment in patients with non-small cell lung cancer (NSCLC)
    Virani, S.
    Almubarak, M.
    Rogers, J. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Second-line treatment options in advanced non-small cell lung cancer: Current status
    Cullen, M
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (01) : S3 - S8
  • [43] Pemetrexed as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Efficacy and correlation with molecular markers
    Blasco, A.
    Sirera, R.
    Terrasa, J.
    Provencio, M.
    Guillen, C.
    Maestu, I.
    de las Penas, R.
    Bover, I.
    Berdiel, M.
    de Aguirre, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)
    Sovak, M. A.
    Lutzker, S.
    Guensch, L.
    Joyce, M.
    Schwartz, S.
    Wu, Y.
    Zheng, L.
    Aisner, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
    Ondhia, Umang
    Conter, H. J.
    Owen, Scott
    Zhou, Anna
    Nam, Julian
    Singh, Sumeet
    Abdulla, Ahmed
    Chu, Paula
    Felizzi, Federico
    Paracha, Noman
    Sanghag, Randeep
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (07) : 625 - 637
  • [46] Efficacy and tolerability of a weekly schedule of docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Binder, D.
    Hackenthal, M.
    Graseck, L.
    Schweisfurth, H.
    Schaeper, C.
    Kruell, M.
    Temmesfeld-Wollbrueck, B.
    Suttorp, N.
    Beinert, T.
    Hellriegel, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Efficacy and toxicity of weekly paclitaxel as second/third line chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Caballero, C
    Camps, C
    Garde, J
    Juarez, A
    Blasco, A
    Berrocal, A
    Safont, M
    Bremnes, R
    Iranzo, V
    Sirera, R
    [J]. LUNG CANCER, 2005, 49 : S239 - S239
  • [48] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S165 - S166
  • [49] Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.
    Fang, Yong
    Pan, Hongming
    Shou, Jiawei
    Hong, Wei
    Guo, Qunyi
    Yang, Xinmei
    Zhu, Dan
    Chen, Jun
    Lu, Liqin
    Rao, Chuangzhou
    Lan, Fen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC):: The STELLAR 2 phase III study
    Bonomi, P
    Paz-Ares, L
    Langer, C
    O'Brien, M
    Gervais, R
    Gatzemeier, U
    Reiterer, R
    Orlov, S
    Ross, H
    Vandenbulcke, J
    [J]. LUNG CANCER, 2005, 49 : S35 - S35
12345